Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Clinical Study of Armored and GPC3-targeted Autologous Chimeric Antigen Receptor (CAR) T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

NCT06590246 is registered in ClinicalTrials.gov with Shanghai AbelZeta Ltd. as lead sponsor.

NCT NCT06590246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06590246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Clinical Study of Armored and GPC3-targeted Autologous Chimeric Antigen Receptor (CAR) T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
Lead sponsor
Shanghai AbelZeta Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 30, 2024
Completion date
April 30, 2043
Enrollment
121 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma